Persistent Coxiella burnetii cardiovascular infection on Bentall-De Bono prosthesis.


Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
May 2020
Historique:
received: 14 11 2019
accepted: 12 01 2020
pubmed: 23 1 2020
medline: 15 12 2020
entrez: 23 1 2020
Statut: ppublish

Résumé

Coxiella burnetii cardiovascular prosthetic infections are associated with high morbidity and mortality and represent a major health problem due to the lack of standardized management. We were confronted with a C. burnetii infection on Bentall-De Bono prosthesis characterized by a history of vascular infection with relapse that prompted us to screen for cases of C. burnetii on Bentall-De Bono vascular prosthesis monitored in our center. We screened patients between 1991 and 2019, from the French national reference center for Q fever. A microbiological criterion in addition to a lesional criterion was necessary to diagnose C. burnetii persistent vascular infection. Two thousand five hundred and eighty two patient were diagnosed with Coxiella burnetii infection and 160 patients with persistent C. burnetii vascular infection prosthesis, 95 of whom had a vascular prosthesis, including 12 with Bentall-De Bono prosthesis. Among patients with persistent C. burnetii prosthetic vascular infection, patients with Bentall-De Bono prostheses were significantly more prone to develop complications such as aneurysm, fistula, and abscess (62 versus 32%, two-sided Chi-square test, p = 0.04). All but one patient were treated with doxycycline and hydroxychloroquine for a mean (± standard deviation) period of 29.4 ± 13.6 months. Among the 12 patients, 5 had cardio-vascular complications, and 5 had prolonged antibiotherapy with doxycycline and hydroxychloroquine. Patients with C. burnetii vascular infection on Bentall-De Bono tend to be at high risk of developing complications (fistula, aneurysm, abscess, death). Surgery is rarely performed. Clinical, serological, and PET scanner imaging follow-up is recommended.

Identifiants

pubmed: 31965366
doi: 10.1007/s10096-020-03816-9
pii: 10.1007/s10096-020-03816-9
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1003-1010

Subventions

Organisme : Fondation Méditerranée Infection
ID : Méditerranée Infection 10-IAHU-03

Références

J Infect. 2012 Aug;65(2):102-8
pubmed: 22537659
Ann Thorac Surg. 2003 Sep;76(3):698-703; discussion 703
pubmed: 12963181
Thorac Cardiovasc Surg Rep. 2018 Jan;7(1):e47-e49
pubmed: 30505643
Eur J Clin Microbiol Infect Dis. 2007 Sep;26(9):635-40
pubmed: 17629755
J Thorac Cardiovasc Surg. 2013 Mar;145(3 Suppl):S78-84
pubmed: 23267525
Lancet. 2012 Jul 28;380(9839):446
pubmed: 22841338
Med Mal Infect. 2019 Mar;49(2):140-149
pubmed: 30722945
Clin Microbiol Rev. 2017 Jan;30(1):115-190
pubmed: 27856520
J Clin Microbiol. 1998 Jul;36(7):1823-34
pubmed: 9650920
Medicine (Baltimore). 2016 Mar;95(12):e2810
pubmed: 27015164
Clin Microbiol Rev. 1999 Oct;12(4):518-53
pubmed: 10515901
Infection. 2017 Dec;45(6):911-915
pubmed: 28779434
Antimicrob Agents Chemother. 2005 Jul;49(7):2673-6
pubmed: 15980335
Lancet. 2016 Feb 27;387(10021):882-93
pubmed: 26341945
Lancet Infect Dis. 2010 Aug;10(8):527-35
pubmed: 20637694
Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5
pubmed: 22378855
Expert Rev Anti Infect Ther. 2020 Jan;18(1):75-86
pubmed: 31782315
J Vasc Surg. 2015 Nov;62(5):1273-80
pubmed: 26365665
Blood. 2016 Jan 7;127(1):113-21
pubmed: 26463422
JAMA Netw Open. 2018 Aug 3;1(4):e181580
pubmed: 30646123
Thorax. 1968 Jul;23(4):338-9
pubmed: 5664694
Yonsei Med J. 2012 Sep;53(5):915-23
pubmed: 22869473
Medicine (Baltimore). 2016 Aug;95(34):e4287
pubmed: 27559944
J Vasc Surg. 2018 Dec;68(6):1906-1913.e1
pubmed: 29685511

Auteurs

Lilya Ghellab (L)

IRD, APHM, MEPHI, Aix-Marseille University, Marseille, France.

Cléa Melenotte (C)

IRD, APHM, MEPHI, Aix-Marseille University, Marseille, France. melenotteclea@gmail.com.
IHU Méditerranée Infection, 19-21 bd Jean Moulin, 13005, Marseille, France. melenotteclea@gmail.com.

Matthieu Million (M)

IRD, APHM, MEPHI, Aix-Marseille University, Marseille, France.

Laury Leveille (L)

Department of Cardiac Surgery, La Timone Hospital, APHM, Marseille, France.

Pascal Thomas (P)

Department of Thoracic Surgery, North Hospital, Aix-Marseille University, APHM, Marseille, France.

Frédéric Collart (F)

Department of Cardiac Surgery, La Timone Hospital, APHM, Marseille, France.

Didier Raoult (D)

IRD, APHM, MEPHI, Aix-Marseille University, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH